The New Frontier of Precision Medicine – From Tumor Fingerprint to Dose: Integrating Data & NGS to Power Neoantigen Therapies

9:30 am - Wednesday 7th October 2026

Presentation Details to be Announced

Right click on the image to save it to your computer.

Speakers:

Kate Sasser
Chief Scientific Officer
Tempus
Said Francis
Chief Business Officer & General Manager, Individualized Neoantigen Therapies
Moderna